OSIRIS THERAPEUTICS
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1992-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.osiris.com/
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
Not Applicable
Completed
- Conditions
- Venous Leg Ulcer
- Interventions
- Other: GrafixPLOther: Control
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT03629236
- Locations
- 🇺🇸
Integral Clinical Trial Solutions, Doral, Florida, United States
🇺🇸SSH, Weymouth, Massachusetts, United States
TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers
Phase 4
Terminated
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Other: TruSkin®Other: Wound Cover
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT02936115
TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers
Phase 4
Terminated
- Conditions
- Chronic Venous Leg Ulcers
- Interventions
- Other: Wound CoverOther: TruSkin
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT02936128
GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers
Phase 4
Completed
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- Procedure: Dressing ApplicationOther: GrafixPRIME®Device: Off-loading (walking boot)
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT02675855
Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
Phase 3
Terminated
- Conditions
- Chronic Diabetic Foot Ulcers
- Interventions
- Other: ControlBiological: CHAM
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 108
- Registration Number
- NCT02571738
- Locations
- 🇺🇸
Center for Clinical Research, San Francisco, California, United States
🇺🇸Barry University Clinical Research, North Miami Beach, Florida, United States
🇺🇸MedStar Georgetown University Hospital, Washington, D.C., District of Columbia, United States
GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds
Phase 4
Completed
- Conditions
- Complex Diabetic Foot Wounds
- Interventions
- Other: Grafix®
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT02260609
- Locations
- 🇺🇸
Carl T. Hayden Medical Research Foundation, Phoenix, Arizona, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, Arizona, United States
🇺🇸Miami VA, Miami, Florida, United States
Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers
Phase 4
Completed
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Other: TissueOther: Control
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Osiris Therapeutics
- Target Recruit Count
- 97
- Registration Number
- NCT01596920
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Omega Medical Research, Warwick, Rhode Island, United States
🇺🇸Blair Orthopedics Associates, Inc, Altoona, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath